A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The company had spent over a decade developing its technology and had conducted an extensive series of clinical assessments that had yielded inconsistent results.


Our immunology expert consultant assessed the scientific underpinnings of the project, the data collected in the clinical programs and the supporting preclinical data and concluded that the company's plans for further development amounted to an effective re-launch rather than a simple extension of work conducted to date. Moreover, we concluded that there was insufficient data to enable an understanding of the factors behind the Phase III trial failure as well as very high risks in embarking on the revamped clinical development plan. We concluded that the probability of technical success in the new program would be a low single digit percentage and consequently the family office declined to follow on its investment.

Explore Our Due Diligence Services

Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate. 

Related Case Studies